Jacqueline Zummo Sells 21,224 Shares of Protara Therapeutics, Inc. (NASDAQ:TARA) Stock

Protara Therapeutics, Inc. (NASDAQ:TARA) insider Jacqueline Zummo sold 21,224 shares of Protara Therapeutics stock in a transaction dated Wednesday, March 26th. The shares were sold at an average price of $4.53, for a total value of $96,144.72. Following the sale, the insider now owns 98,861 shares of the company’s stock, valued at approximately $447,840.33. This trade represents a 17.67 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.

Protara Therapeutics Stock Up 0.9 %

Protara Therapeutics stock opened at $4.58 on Friday. The firm has a fifty day simple moving average of $4.27 and a two-hundred day simple moving average of $3.67. Protara Therapeutics, Inc. has a twelve month low of $1.60 and a twelve month high of $10.48. The company has a market capitalization of $168.39 million, a PE ratio of -1.62 and a beta of 1.69.

Protara Therapeutics (NASDAQ:TARA) last released its earnings results on Wednesday, March 12th. The company reported ($0.48) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.57) by $0.09. As a group, equities analysts expect that Protara Therapeutics, Inc. will post -3.32 earnings per share for the current fiscal year.

Institutional Trading of Protara Therapeutics

A number of institutional investors have recently made changes to their positions in TARA. XTX Topco Ltd bought a new stake in Protara Therapeutics during the 3rd quarter valued at $60,000. HBK Investments L P purchased a new position in shares of Protara Therapeutics in the fourth quarter valued at about $106,000. Squarepoint Ops LLC bought a new position in shares of Protara Therapeutics during the fourth quarter valued at about $110,000. Dimensional Fund Advisors LP purchased a new stake in shares of Protara Therapeutics during the fourth quarter worth about $111,000. Finally, Bailard Inc. bought a new stake in shares of Protara Therapeutics in the fourth quarter worth about $157,000. Hedge funds and other institutional investors own 38.13% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on the stock. HC Wainwright reiterated a “buy” rating and set a $23.00 target price on shares of Protara Therapeutics in a research report on Thursday, March 6th. Cantor Fitzgerald began coverage on shares of Protara Therapeutics in a research report on Friday, March 14th. They issued an “overweight” rating for the company. Guggenheim restated a “buy” rating and set a $20.00 price target on shares of Protara Therapeutics in a research report on Friday, December 6th. Finally, Lifesci Capital assumed coverage on Protara Therapeutics in a report on Tuesday, March 11th. They issued an “outperform” rating and a $22.00 price objective for the company. Five research analysts have rated the stock with a buy rating, According to MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $22.50.

Protara Therapeutics Company Profile

Protara Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.